Lausanne, Vaud, Switzerland The leading representative office of defined VC is situated in the Martigny. The venture was found in Europe in Switzerland.
Among the most popular fund investment industries, there are Search Engine, MOOC. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Switzerland. Among the most popular portfolio startups of the fund, we may highlight Kaiku Health, Diagnoplex, BC Platforms.
This organization was formed by Tanja Dowe. We also calculated 4 valuable employees in our database.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Debiopharm Innovation Fund, startups are often financed by Venture Kick, Johnson & Johnson Development Corporation, Debiopharm Group. The meaningful sponsors for the fund in investment in the same round are Tesi, Wellcome Trust, Valiance Asset Management. In the next rounds fund is usually obtained by Truffle Capital, Swisscom Ventures, Serena.
The top amount of exits for fund were in 2015. The common things for fund are deals in the range of 10 - 50 millions dollars. This Debiopharm Innovation Fund works on 4 percentage points more the average amount of lead investments comparing to the other organizations. The high activity for fund was in 2013. Despite it in 2019 the fund had an activity. The fund is generally included in less than 2 deals every year. The real fund results show that this VC is 36 percentage points more often commits exit comparing to other companies.
Related Funds
Funds with similar focus
| Fund Name | Location |
| AHLI FINTECH | Amman, Amman, Jordan |
| Andrew Carter Capital | Dallas, Texas, United States |
| Arts Alliance Media | England, London, United Kingdom |
| Asigin Research institute Ltd. | Japan, Tochigi Prefecture, Utsunomiya |
| Biotel | - |
| Boehringer Ingelheim | Germany, Ingelheim Am Rhein, Rheinland-Pfalz |
| BSKG Holdings | - |
| Gamnat | Central, Central Region, Singapore |
| Glass Wall Syndicate | - |
| Innovative Medicines Initiative | Belgium, Berchem, Brussels-Capital |
| Kowa | Aichi Prefecture, Japan, Nagoya |
| MediaOne Ventures | - |
| Metagal | - |
| QUI! GROUP | Genova, Italy, Liguria |
| Sirios Capital Management | Boston, Massachusetts, United States |
| StratMinds | California, San Francisco, United States |
| Swift River Investments | Bolton, Massachusetts, United States |
| TDH Capital | Pennsylvania, Radnor, United States |
| V V Pentafond | - |
| Visit Intelligence Oy | Finland, Parainen, Southwest Finland |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
OmicsChart | $354K | 09 Oct 2023 | Munich, Bayern, Germany | ||
Altis Labs | $6M | 21 Jun 2023 | Toronto, Ontario, Canada | ||
ConcR | $986K | 05 May 2023 | London, England, United Kingdom | ||
Genialis | $13M | 29 Mar 2023 | Houston, Texas, United States | ||
Iktos | $18M | 09 Mar 2023 | Paris, Ile-de-France, France | ||
YonaLink | $6M | 09 Nov 2022 | Jerusalem, Jerusalem District, Israel | ||
Mika | $11M | 09 May 2022 | Berlin, Berlin, Germany | ||
VivoSense | $25M | 30 Mar 2022 | Newport Coast, California, United States | ||
Nucleai | $33M | 22 Mar 2022 | Tel Aviv-Yafo, Tel Aviv District, Israel |
– Carevive Systems (Carevive), the leading oncology-focused health technology company centered on understanding and improving the cancer patient experience, has today announced the completion of a Series C equity investment of $18 million.
– The oversubscribed $18 million equity round was led by Philips Health Technology Ventures, and also includes Debiopharm Innovation Fund, and OurCrowd’s digital health fund, Qure Ventures, as well as prior investors HLM Venture Partners, LRVHealth, Cerner, and founder Madelyn Trupkin Herzfeld.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
OmicsChart | $354K | 09 Oct 2023 | Munich, Bayern, Germany | ||
Altis Labs | $6M | 21 Jun 2023 | Toronto, Ontario, Canada | ||
ConcR | $986K | 05 May 2023 | London, England, United Kingdom | ||
Genialis | $13M | 29 Mar 2023 | Houston, Texas, United States | ||
Iktos | $18M | 09 Mar 2023 | Paris, Ile-de-France, France | ||
YonaLink | $6M | 09 Nov 2022 | Jerusalem, Jerusalem District, Israel | ||
Mika | $11M | 09 May 2022 | Berlin, Berlin, Germany | ||
VivoSense | $25M | 30 Mar 2022 | Newport Coast, California, United States | ||
Nucleai | $33M | 22 Mar 2022 | Tel Aviv-Yafo, Tel Aviv District, Israel |
